8-K

                       SECURITIES AND EXCHANGE COMMISSION

                           Washington, D. C. 20549

                                    FORM 8-K

                                 CURRENT REPORT


     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

      Date of report (Date of earliest event reported) September 15, 2003


                           BARR LABORATORIES, INC.
            (Exact name of registrant as specified in its charter)


        New York                    1-9860                   22-1927534
(State or other jurisdiction      (Commission               (IRS Employer
     of incorporation)            File Number)            Identification No.)


Two Quaker Road, P.O. Box 2900, Pomona, New York          10970-0519
(Address of principal executive offices)                  (Zip code)


                                 (845) 362-1100
             (Registrant's telephone number, including area code)

Item 5. Other Events and Regulation FD Disclosure.

On September 15, 2003, Barr Laboratories, Inc. issued a press release
acknowledging the decision by the U.S. District Court for the District of
Minnesota in the suit between Natural Biologics, LLC and Wyeth. The decision
permanently enjoins Natural Biologics from selling equine-based conjugated
estrogens raw material and orders Natural Biologics to withdraw its Drug Master
File (DMF) for equine-based conjugated estrogens raw material from the U.S. Food
& Drug Administration (FDA). The Company said that it would review its options
regarding the application and is assessing the potential financial impact of the
decision. The Company is informed that Natural Biologics will either seek a
re-hearing or appeal the District Court ruling. The ultimate resolution will
depend on the outcome of these further proceedings. A copy of the release is
attached hereto as Exhibit 99.0 and is incorporated herein by reference.



Exhibit Number         Exhibit
- --------------         -------
                    
      99.0             Barr Laboratories, Inc. September 15, 2003 press
                       release


                                   SIGNATURES


Pursuant to the requirements of the Securities and Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                 BARR LABORATORIES, INC.

Date:  September 15, 2003        /s/ William T. McKee
                                 ------------------------------------------
                                 William T. McKee
                                 Senior Vice President, Chief Financial Officer,
                                 and Treasurer

EX-99.0

                                                                    Exhibit 99.0

[BARR LABORATORIES, INC. GRAPHIC]
400 Chestnut Ridge Road                                             NEWS RELEASE
Woodcliff Lake, NJ 07677
201-930-3300


CONTACT:    Carol A. Cox, 201-930-3720    EMAIL:  ccox@barrlabs.com

Barr To Review Options Following District Court Ruling on Natural Biologics'
Generic Premarin(R) Raw Material

WOODCLIFF LAKE, NJ - SEPTEMBER 15, 2003...Barr Laboratories, Inc. (NYSE-BRL)
today acknowledged that the decision by the U.S. District Court for the District
of Minnesota in the suit between Natural Biologics, LLC and Wyeth instructs
Natural Biologics to withdraw its Drug Master File (DMF) for equine-based
conjugated estrogens raw material from the U.S. Food & Drug Administration (FDA)
and consequently, if the ruling stands, Barr will not be allowed to use the raw
material in its pending application for an AB-rated conjugated estrogens
product. The Company said that it would review its options regarding the
application and is informed that Natural Biologics will either seek a re-hearing
or appeal the District Court ruling. The ultimate resolution will depend on the
outcome of these further proceedings.

"The decision by Minnesota District Court Judge Joan N. Ericksen is a set-back
in our continuing efforts to develop a product that is AB-rated to Wyeth's
Premarin, but we will continue our efforts to bring a generic version of
Premarin to market," said Bruce L. Downey, Barr's Chairman and Chief Executive
Officer.

In March 2002, Barr announced that it had signed a series of agreements with
Natural Biologics to develop an "AB" rated conjugated estrogens product based on
Natural Biologics' equine-based raw material and on June 30, 2003 Barr filed its
application with the FDA. Barr is currently owed approximately $16 million in
principal and interest by Natural Biologics under these agreements and the
Company is currently evaluating the potential impact of these legal proceedings
on the collectibility of these amounts.

Barr Laboratories, Inc. is engaged in the development, manufacture and
marketing of generic and proprietary pharmaceuticals.

Safe Harbor Statement: To the extent that any statements made in this report
contain information that is not historical, these statements are essentially
forward-looking. Forward-looking statements can be identified by the use of
words such as "expects," "plans," "will," "may," "anticipates," "believes,"
"should," "intends," "estimates," and other words of similar meaning. These
statements are subject to risks and uncertainties that cannot be predicted or
quantified and, consequently, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such risks and
uncertainties include: the difficulty in predicting the timing and outcome of
legal proceedings, including those relating to patent challenge settlements and
patent infringement cases; the difficulty of predicting the timing of U.S. Food
and Drug Administration, or FDA, approvals; court and FDA decisions on
exclusivity

[BARR LABORATORIES, INC. GRAPHIC]

periods; the ability of competitors to extend exclusivity periods for their
products; market and customer acceptance and demand for our pharmaceutical
products; reimbursement policies of third party payors; our ability to market
our proprietary products; the successful integration of acquired businesses and
products into our operations; the use of estimates in the preparation of our
financial statements; the impact of competitive products and pricing; the
ability to develop and launch new products on a timely basis; the availability
of raw materials; availability of any product we purchase and sell as a
distributor; the regulatory environment; fluctuations in operating results,
including spending for research and development, sales and marketing and patent
challenge activities; and, other risks detailed from time-to-time in our filings
with the Securities and Exchange Commission. The Company undertakes no
obligation to publicly update any forward-looking statements.

[EDITOR'S ADVISORY: Barr Laboratories, Inc. news releases are available free of
charge through PR Newswire's News On-Call site at http://www.prnewswire.com/corp
/089750.html. Barr news releases and corporate information are also available
on Barr's website (www.barrlabs.com). Premarin(R) is a registered trademark of
Wyeth.]

                                    # # #